Biotek-snakken — Juni 2025
-
Bristol Myers betaler $11 mia for halvpart i Biontech middel https://proinvestor.com/boards/126603
-
$Jazz leverer flotte data fra Zani i ph2 1L mGEA . https://lifesciencereport.com/news/nasdaq/jazz/jazz-pharmaceuticals-reports-clinically-meaningful-long-term-median-overall-survival-data-for-ziihera-zanidatamab-hrii-in-first-line-her2-positive-metastatic-gastroesophageal-adenocarcinoma-at-asco-2025
-
Fedmemarkedet handler primært om glp1, senere er amylin blevet kendt, men det dansk-svenske biotekselskab Pila Pharma, grundlagt af Dorte X. Gram med rødder i Novo Nordisk, udvikler en oral behandling mod type 2-diabetes og fedme baseret på en såkaldt chili-receptor. Hør mere i denne video, hvor Helge Larsen har besøg af Dorte X. Gram https://proinvestor.com/boards/126647
-
Europa/aktier: Sundhedsaktier vinder frem mens investorer kigger mod toldforhandlinger https://proinvestor.com/investornyt/1325611/europa-aktier-sundhedsaktier-vinder-frem-mens-investorer-kigger-mod-toldforhandlinger
-
2025-05-06 HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS https://ir.halozyme.com/news/news-details/2025/HALOZYME-RAISES-2025-FINANCIAL-GUIDANCE-RANGES-AND-REPORTS-STRONG-FIRST-QUARTER-2025-RESULTS/default.aspx
-
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models
/PRNewswire/ -- DeepCure, an immunology therapeutics company leveraging artificial intelligence (AI) to rapidly advance novel small molecule drugs, today...
(www.prnewswire.com)
-
-
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in preclinical studies --Investigational New Drug (IND)-enabling activities ongoing to support IND submission later this year SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targe
Yahoo Finance (finance.yahoo.com)
-
Biotech financing: divide and reset https://www.nature.com/articles/s41587-025-02723-8 Nature Biotechnology
jazzz ja nogen ved hvis noget men vi tager gladelig det hele med Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind